Key clinical point: Second allogeneic transplant is an effective salvage therapy option after relapse in children with lymphoid cancers or myelodysplastic diseases.
Major finding: 3-year overall survival was 26% for children who had a second transplant vs. 4% for those who did not.
Study details: Retrospective study of 221 patients aged 21 years and younger who had a relapse after stem cell transplant for ALL, AML, or MDS.
Disclosures: The study was supported by St. Jude’s, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Dr. Sharma, Dr. Boelens, and Dr. Duerst reported having no relevant disclosures.
Sharma A et al. TCT 2020, Abstract 116.